• Q3FY25 sales of US$4.7 million, up 27% on prior corresponding period
• USA sales up 32% to highest level in company history
• Glaucoma segment EBITDA-level loss reduced to US$30 thousand
• FY25 revenue guidance (excluding China) confirmed between A$27.5-A$29.1 million

Nova Eye Medical Limited, a medical technology company focused on advanced ophthalmic treatment technologies and devices, reported strong operational and financial results for the March 2025 quarter. Key highlights include a 27% year-over-year growth in Q3FY25 sales (excluding China), driven by a 32% increase in USA sales, which reached the highest level in the company's history. The glaucoma segment also saw a substantial improvement in profitability, with the EBITDA-level loss reduced to US$30 thousand in Q3FY25 compared to a US$1.79 million loss in H1FY25. The company's balance sheet was further strengthened by a successful A$6.6 million capital raising in February 2025. Additionally, Nova Eye Medical identified new revenue opportunities by leveraging its proprietary iTrack technology for targeted ocular drug delivery, a market projected to grow from US$6.89 billion in 2024 to US$12.59 billion by 2034. Over the next 12 months, the company plans to generate clinical validation data, refine the technology, and assess commercialization pathways with strategic partners. The company also confirmed its FY25 revenue guidance (excluding China) between A$27.5 and A$29.1 million, with the glaucoma segment expected to achieve profitability in H2FY25.

Revenue for H2FY25 (excluding China sales) is expected to range between US$9.0 and US$10 million, reflecting growth of 15%-30% over H1FY25. Full-year FY25 revenue (excluding China sales) is projected between A$27.5 and A$29.1 million. The glaucoma segment is expected to achieve profitability in H2FY25, although the level of Q4FY25 sales to China may impact the operating result.

Over the next 12 months, Nova Eye Medical intends to generate clinical validation data, refine its technology for targeted drug delivery applications, and assess commercialisation pathways with strategic partners.